^
Association details:
| Biomarker: | HER-2 negative |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | AiTan (rivoceranib) (VEGFR-2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Single-arm, open-label, prospective study for apatinib combined with AI inhibitors in patients with advanced HER2-negative, HR-positive breast cancer
Excerpt:
...Metastatic HER2-negative, HR+ breast cancer with measurable lesions confirmed by histology or cytology; 2. ...
Trial ID:
Source:
Title:
Fulvestrant combined with apatinib in patients with hormone receptor-positive, HER-2 negative advanced breast cancer: a phase 2, single-arm, prospective study
Excerpt:
...Histologically diagnosis of hormone receptor positive (ER and/or PR+), HER2 negative breast cancer(ER positive: immunohistochemistry (IHC) ＞1% tumor cell staining; PR positive: immunohistochemistry (IHC) ＞1% tumor cell staining; HER-2 negative: immunohistochemistry 0, 1+, or 2+ while FISH/CISH negative); 3. ...
Trial ID:
More C2 evidence
Source:
Title:
Apatinib for pretreated HER2-negative breast cancer: a single arm, single center, observational clinical trial
Excerpt:
...(1) Signed Informed Consent Form(ICF); (2) Women aged 18 to 75 years; (3) Eastern Cooperative Oncology Group(ECOG) Performance Status 0-1; (4) Expected survival more than 12 weeks; (5) Histologically or cytologically confirmed invasive breast cancer, including locally advanced breast cancer (stage IIIb, stage IIIc) or recurrent and metastatic breast cancer; (6) HER2 negative confirmed by our laboratory tests (HER2 negative definition: IHC + or ISH-, if IHC2 + then ISH-); (7) At least one measurable lesion according to RECIST version 1.1 criteria; (8) At least failure of one chemotherapeutic regimen (combined or non-combined targeted therapy), and the progression needs to be confirmed by imaging; (9) Baseline LVEF >= 50% by ECHO; (10) Adequate organ function (bone-marrow, liver, renal and coagulation function) within 7 days prior to the first study treatment: 1) Leukocyte >= 3.0x10^9/L, neutrophil (ANC) >= 1.5x10^9/L, platelet count (PLT) >= 90x10^9/L, hemoglobin >=90 g/L; 2) Serum total bilirubin (TBIL) ...
Trial ID:
Source:
Title:
A Study of Fluzoparib±Apatinib Versus Chemotherapy Treatment of Physician's Choice in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation
Excerpt:
...- （Saftey Lead-in + phase 3）human epidermal growth factor receptor type 2 (HER2)-negative metastatic breast cancer...
Trial ID:
Source:
Title:
Prospective, Multicenter, Observational Study of Apatinib Single or Combined Capecitabine for Treatment of Patients With Metastatic Her-2 Negative Breast Cancer
Excerpt:
...- Pathologically diagnosed with her-2 negative, ER/PR negative, ER/PR positive after the failure of endocrine treatment, and had...
Trial ID:
Source:
Title:
Apatinib mesylate tablets combined with docetaxel for the taxane based chemotherapy in the treatment of the failure of HER-2 negative metastatic breast cancer prospective, open, single arm clinical study
Excerpt:
...HER-2 negative metastatic breast cancer diagnosed by pathology recurrence: HER-2 negative immunohistochemical criteria for definite HER-2 (- / + / +), HER-2 (+ +), if need FISH/CISH confirmed that HER-2 amplification was negative; 4. ...
Trial ID:
Source:
Title:
Combination Neoadjuvant Chemotherapy With or Without Apatinib for HER2 Negative Breast Cancer
Excerpt:
...HER2-negative tumor in biopsy, defined as: Immunohistochemical (IHC) 0-1+ or IHC 2+ confirmed as FISH negative....
Trial ID:
Source:
Title:
Apatinib With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2- Advanced Breast Cancer
Excerpt:
...defined as HER2 negative);...
Trial ID:
Source:
Title:
A Randomized, Controlled, Open-label Clinical Trial of Adjuvant Intensive Therapy for HR+/ HER2-SNF4 Early Breast Cancer
Excerpt:
...defined as HER2 negative); 3....
Trial ID:
Source:
Title:
Vinorelbine Plus Apatinib Versus Vinorelbine in Advanced Triple-Negative Breast Cancer
Excerpt:
......
Trial ID:
Source:
Title:
Multicenter Phase II Study of Apatinib in Patients With Advanced Breast Cancer(CABC006)
Excerpt:
...HER-2 negative advanced breast cancer with chest wall metastasis confirmed by histology or cytological examination (patients who have received anthracyclines and/or paclitaxel in adjuvant chemotherapy)....
Trial ID:
Source:
Title:
Apatinib Combined With Oral Etoposide in Metastatic HER2 Negative Breast Cancer
Excerpt:
...- Age between 18 and 75 year-old women; HER2 negative(immunohistochemistry or fluorescence in situ hybridization); -...
Trial ID:
Less C2 evidence
Source:
Title:
The anti-tumor efficiency of low-dose apatinib-based chemotherapy in pretreated HER2-negative breast cancer with brain metastases
Published date:
06/01/2023
Excerpt:
The CNS-ORR was 17.2% (95%CI 9.6% to 28.9%) and the CBR was 53.4% (95%CI 40.8% to 65.7%). The median duration of CNS-PFS for the entire cohort was 6.4 months, and the median OS was 10.7 months….Apatinib-based chemotherapy demonstrates potential feasibility with acceptable tolerance for HER2-negative BCBM.
Secondary therapy:
Chemotherapy
DOI:
https://doi.org/10.1080/07853890.2023.2218647
Source:
Title:
247P - Apatinib combined with chemotherapy versus single chemotherapy in advanced HER-2-negative breast cancer: A randomized, controlled, open-label phase II study
Published date:
09/05/2022
Excerpt:
Median PFS was significantly longer in the apatinib group than in the single chemotherapy group (182 days vs 63 days; P=0.043)...Apatinib combined with chemotherapy in treating advanced HER2-negative breast cancer showed encouraging efficacy with a manageable safety profile...
Secondary therapy:
Chemotherapy
Source:
Title:
Phase II study of apatinib in combination with oral vinorelbine in heavily pretreated HER2-negative metastatic breast cancer and clinical implications of monitoring ctDNA
Published date:
05/26/2021
Excerpt:
All-oral therapy with apatinib plus vinorelbine displayed objective efficacy in patients with heavily pretreated HER2-negative mBC, with acceptable and manageable toxicity profiles.
Secondary therapy:
vinorelbine
DOI:
10.20892/j.issn.2095-3941.2020.0418
